ADOCIA Confirms Its Eligibility for the PEA–PME
June 06 2024 - 12:00PM
Business Wire
Regulatory News:
Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage
biopharmaceutical company focused on the research and development
of innovative therapeutic solutions for the treatment of diabetes
and other metabolic diseases, confirms its eligibility for the “PEA
– PME” stock savings tax regime, which decree has been published in
the French Journal Officiel on March 4, 2014 (Decree n ° 2014-283),
and which entered into force on March 6, 2014.
To be eligible for the “PEA – PME”, the shares must have been
issued by a company whose market capitalization is below one
billion euros, which has less than 5,000 employees, and an annual
turnover not exceeding 1.5 billion euros or a total balance sheet
less than 2 billion euros.
Adocia meets all of these conditions.
About Adocia
Adocia is a biotechnology company specializing in the discovery
and development of therapeutic solutions in the field of metabolic
diseases, primarily diabetes and obesity.
The company has a broad portfolio of drug candidates based on
four proprietary technology platforms: 1) The BioChaperone®
technology for the development of new generation insulins and
products combining different hormones; 2) AdOral®, an oral peptide
delivery technology; 3) AdoShell®, an immunoprotective biomaterial
for cell transplantation, with an initial application in pancreatic
cells transplantation; and 4) AdoGel®, a long-acting drug delivery
platform.
Adocia holds more than 25 patent families. Based in Lyon, the
company has about 80 employees. Adocia is listed on the regulated
market of Euronext™ Paris (Euronext: ADOC; ISIN: FR0011184241).
Disclaimer
This press release contains certain forward-looking statements
concerning Adocia and its business. Such forward-looking statements
are based on assumptions that Adocia considers as being reasonable.
However, there can be no guarantee that the estimates contained in
such forward-looking statements will be achieved, as such estimates
are subject to numerous risks including those set forth in the
“Risk Factors” section of the universal registration document that
was filed with the French Autorité des marchés financiers on April
29, 2024, available at www.adocia.com. Those risks include
uncertainties inherent in Adocia's short- or medium-term working
capital requirements, in research and development, future clinical
data, analyses and the evolution of economic conditions, the
financial markets and the markets in which Adocia operates, which
could impact the Company's short-term financing requirements and
its ability to raise additional funds. The forward-looking
statements contained in this press release are also subject to
risks not yet known to Adocia or not considered as material by
Adocia at this time. The occurrence of all or part of such risks
could cause the actual results, financial conditions, performances,
or achievements of Adocia be materially different from those
mentioned in the forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240606270803/en/
Adocia Olivier Soula CEO
contactinvestisseurs@adocia.com +33 (0)4 72 610 610
www.adocia.com
Ulysse Communication Adocia Press & Investor
Relations Bruno Arabian Nicolas Entz
adocia@ulysse-communication.com + 33 (0)6 87 88 47 26
Edoc Acquisition (NASDAQ:ADOC)
Historical Stock Chart
From Jul 2024 to Aug 2024
Edoc Acquisition (NASDAQ:ADOC)
Historical Stock Chart
From Aug 2023 to Aug 2024